We want clients and members to get the most out of their benefit and the cost of a drug is aligned with the value it delivers. Despite AWP inflation near 10%, we kept drug price... More
A few key metrics can help demonstrate how well a value-based management approach is working in helping align drug prices with the value and outcomes they deliver. More
The current model of static, manufacturer-set drug prices is simply unsustainable. Value-based management approaches attempt to incentivize quality and efficacy. More
Manufacturer-driven brand inflation contributed 8.6 percentage points to trend, while PBM management solutions, helped reduce it by 7.8 percentage points. Thirty eight percent of... More
Despite ongoing price inflation and an increase in utilization, prescription drug trend dropped for a majority of CVS Health pharmacy benefit management (PBM) clients in the first... More
In 2014, prescription benefit trend climbed to double digits, spurring many payors to adopt more aggressive management strategies. Among these, an aggressive approach to formulary... More
Over the last few years, the dermatological category has emerged as a top driver of drug trend. In 2015, the category trended at 39.5 percent and its impact on our gross trend was... More
While trend drivers—including brand, specialty and generic price inflation—were similar to those in 2014, broad adoption of proactive CVS Caremark cost management strategies... More